Sirolimus

Last Updated: 03/28/17

Status: Potential NF2 Clinical Trial

Index

  1. Basic Information
  2. Clinical Trials
  3. Side Effects

1. Basic Description:

Sirolimus (INN/USAN), also known as Rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. Sirolimus is also a medication that has been in trial for NF2 tumors.

2. Unrelated Clinical Trials:

  • Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC) - www.ClinicalTrials.gov
  • A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis - www.ClinicalTrials.gov

3. Serious Side Effects:

  • Increase Risk of Infections or Cancer - Lymphoma (Cancer of the Immune System) and Skin Cancer
  • If you had Liver or Lung Transplants, may cause serious side effects or death

Common Side Effects:

  • Fever
  • Chills
  • Frequent or Painful Urination
  • Night Sweats
  • Chest Pain
  • General Pain
  • Constant Weakness or Tiredness
  • Fullness in the Stomach
  • Unexplained Weight Loss
  • Unusual Bleeding or Bruising
  • Skin Issues -
    • Sores
    • Swelling
    • Red Skin
    • Racked Skin
    • Hives
    • Rash
    • Itching
  • Throat Issues -
    • Trouble Breathing
    • Swallowing
    • Cough
    • Sore Throat
    • Hoarseness
  • Swelling -
    • Neck Glands
    • Armpits
    • Groin
    • Face
    • Throat
    • Tongue
    • Lips
    • Eyes
    • Hands
    • Feet
    • Ankles
    • Lower Legs

Additional Possible Side Effects:

  • Headache
  • Constipation
  • Diarhhea
  • Nausea
  • Joint Pain
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017